Natera's EDEN Study Targets Early Preeclampsia Prediction

AUSTIN, TX – February 06, 2026 – Natera, a prominent leader in cell-free DNA (cfDNA) diagnostics, has announced the launch of a major clinical trial aimed at transforming prenatal care. The EDEN study, a large-scale, multi-center prospective trial, will evaluate a novel non-invasive test designed for the early risk assessment of preeclampsia, a dangerous and often unpredictable pregnancy complication.

By analyzing a combination of genetic signals, biomarkers, and clinical data from a simple blood draw, the company hopes to provide expectant parents and their doctors with a crucial early warning system, potentially months before any symptoms of the disease emerge.

The Urgent Need for Better Prediction

Preeclampsia is a formidable challenge in modern obstetrics. Affecting an estimated 5-8% of pregnancies worldwide, the hypertensive disorder is a leading cause of maternal and infant illness and death. It is typically diagnosed after 20 weeks of gestation, marked by new-onset high blood pressure and signs of organ damage, such as protein in the urine or impaired liver and kidney function. For Black women in the United States, the risk is even greater, as they face both higher incidence and more severe outcomes from the condition.

The only definitive cure for preeclampsia is delivery of the baby and placenta, which can lead to medically necessary preterm births and associated complications for the newborn. Current screening relies heavily on routine blood pressure measurements taken at prenatal visits—a method that is reactive rather than predictive. By the time blood pressure rises, the underlying disease process is already well underway.

Leading medical bodies, including the American College of Obstetricians and Gynecologists (ACOG), have acknowledged the significant limitations of existing screening protocols. While low-dose aspirin is recommended for patients with known risk factors, identifying who will truly benefit remains a challenge. Current risk assessment models that rely on clinical characteristics often lack precision and provide poor individualized risk estimates, with positive predictive values often falling below 35%. This means many women flagged as high-risk will never develop the condition, leading to unnecessary anxiety and interventions, while others at true risk are missed.

This diagnostic gap underscores a critical unmet need for a more accurate, personalized, and earlier method of identifying pregnancies at high risk for developing preeclampsia and other adverse outcomes.

Natera's DNA-Based Approach

Natera aims to fill this void by leveraging its deep expertise in cell-free DNA analysis. The company's new integrated test combines cfDNA signals, which are tiny fragments of DNA from the placenta circulating in the mother's bloodstream, with other biomarkers and maternal clinical data. The goal is to create a comprehensive risk score early in pregnancy, between 9 and 15 weeks’ gestation.

This approach is built on a solid foundation of prior research. Studies have demonstrated that specific characteristics of cfDNA, such as its methylation patterns and the proportion of DNA originating from the placenta, can serve as powerful early indicators of placental dysfunction—the root cause of preeclampsia. This method offers a direct window into the biological health of the placenta long before clinical symptoms manifest.

“For more than a decade, Natera has advanced pregnancy care through highly sensitive, non-invasive testing,” said Sheetal Parmar, senior vice president of medical affairs at Natera, in the company's press release. “With EDEN, we are evaluating a next-generation test designed to identify pregnancies at increased risk for preeclampsia and other serious complications earlier and with greater precision, using data that are already part of routine prenatal care.”

The EDEN (Early DNA-based pEreeclampsia aNd adverse outcomes) study is designed to be a definitive trial. By enrolling up to 7,500 pregnant participants across the United States and following them prospectively through delivery, Natera seeks to rigorously validate the test's performance in a real-world setting. This robust study design is essential for generating the high-quality evidence needed to shift clinical practice.

Navigating a Competitive Diagnostic Landscape

Natera is not alone in the race to solve the preeclampsia puzzle. The significant market opportunity and pressing clinical need have attracted a number of innovative companies. Competitor Mirvie is developing a test that analyzes RNA messages to predict risk, while established diagnostic giants like Roche, PerkinElmer, and Thermo Fisher Scientific offer tests that measure protein biomarkers—namely placental growth factor (PlGF) and soluble fms-like tyrosine kinase-1 (sFlt-1)—to aid in diagnosis, typically later in pregnancy.

These protein-based tests have already gained traction, particularly in Europe, and are supported by guidelines from organizations like the Fetal Medicine Foundation, which advocates for a first-trimester screening algorithm combining maternal factors, blood pressure, and biomarkers. Natera's strategy, however, is to go a level deeper by analyzing the DNA-level signals that precede changes in protein and RNA. This focus on cfDNA could be a key differentiator, potentially offering an earlier and more direct signal of placental health than other methods.

The Path to Market and Patient Impact

The potential market for an effective early preeclampsia screen is substantial, with analysts projecting the global market for preeclampsia diagnostics to surpass $2 billion by 2029. However, the path from a promising clinical trial to a widely adopted and reimbursed standard of care is long and challenging.

Even with a successful outcome, the EDEN study is just the beginning. The enrollment of 7,500 participants and the subsequent follow-up period mean that definitive results are likely three to five years away. Following data analysis, Natera will face the rigorous process of regulatory review. The ultimate hurdle, however, will be securing reimbursement from insurance payers.

Payers will demand more than just proof of predictive accuracy; they will require evidence of clear clinical utility. Natera will need to demonstrate that its test not only identifies at-risk patients but that this early identification leads to interventions that tangibly improve maternal and fetal outcomes and reduce overall healthcare costs. The widespread adoption of non-invasive prenatal screening (NIPS) for chromosomal abnormalities, another cfDNA-based technology pioneered by Natera, sets a positive precedent, but each new diagnostic must prove its own value. The EDEN study is a critical investment in building that case, one that holds the potential to redefine risk assessment in pregnancy for years to come.